Search Protocols under revision. Back New search Go to resultsDiseaseMain groupHematologic NeoplasmsProtocol groupMyeloid/Lymphoid Neoplasms with Eosinophilia and Tyrosine Kinase FusionDiseaseChronic eosinophilic leukemia, not further specifiedSubgroupICD10D47.5MeSHHypereosinophilic SyndromeSequenceChemotherapyChemo-substanceHydroxyureaChemo-substanceHydroxyureaChemo-substanceHydroxyureaChemo-substanceHydroxyureaNo. Substances1 RadiotherapySupportive therapySupportive substanceSupportive substanceSupportive substanceSupportive substanceNo. SubstancesProtocol classificationTherapy classificationcurrent standardIntensityStandard doseTherapy indicationseveral possibleTherapy phaseTherapy intentiondisease controlRisksEmetogenicity (ASCO) only studiesPublicationAuthorShomali WDiseaseChronische EosinophilenleukämieOriginStanford Cancer Institute/Stanford University School of Medicine, Stanford, California, USAProtokolle in Überarbeitung 1 protocol foundHydroxyurea 500, Chronic Eosinophilic Leukemia (PID3254 V1.0)
